Biotech Values

[vinmantoo]

ENTA’s partial monetization of the Mavyret royalty stream is a wise move (IMO), although they probably should have done it sooner. I commented on this in #msg-166883690.

I agree it is a good move. ENTA was going to have to raise cash in a year or so, and with big rise in interest rates over the last year, if they didn't do this they were facing either dilutive financing or a loan on less favorable terms than in a long while.